Page last updated: 2024-12-07
sulacillin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
sulacillin: a combination of ampicillin & sulbactam used in the treatment of infectious complications & bronchopulmonary diseases; a Russian compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 119561 |
| MeSH ID | M0238486 |
Synonyms (11)
| Synonym |
|---|
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s-(2-alpha,5-alpha,6-beta(s*)))-, mixt. with (2s-cis)-3,3-dimethyl-7-oxo-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide |
| ampicillin sodium and sulbactam sodium |
| 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(((2r)-aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-, mixt. with (2s,5r)-3,3-dimethyl-7-oxo-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid 4,4-dioxide |
| ampicillin-sulbactam |
| ampicillin and sulbactam |
| sulbactam-ampicillin mixt. (1:2) |
| sulacillin |
| 94935-63-4 |
| ampicillin-sulbactam mixt. |
| DTXSID60241694 |
| (2s,5r,6r)-6-[[(2r)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(1r,4s)-3,3-dimethyl-2,2,6-trioxo-2lambda6-thiabicyclo[3.2.0]heptane-4-carboxylic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (3)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||